Project profile: Mol Cancer Med

Developing Molecular Medicines for Cancer in the Post - Genome Era

Acronym: Mol Cancer Med

Project Number: LSH-CT-2004-502943

EC Contribution: 4,000.000 Euros

Duration: 48 months

Starting date: 01/10/04

Instrument: Integrated Project

Coordinator: Professor R F Newbold, Institute of Cancer Genetics and  Pharmacogenomics, Brunel University, Uxbridge, Middlesex, UB8 3PH, UK

Email: robert.newbold@brunel.ac.uk

Project website: www.brunel.ac.uk/mol-cancer-med

Short summary: The cellular immortality enzyme telomerase (one of the  Most promising universal cancer markers) and associated telomere maintenance mechanisms represent novel anti-cancer targets of enormous therapeutic and diagnostic potential. In Mol Cancer Med, a multinational EU translational cancer research consortium has been established, in which expert cancer geneticists and molecular biologists will interact with prominent pharmacologists, clinicians and pathologists to develop, within a 4-year time-frame, these exciting new cellular targets into measurable pre-clinical advances.

Page last updated: Friday 15 July 2011